目的 探讨复方斑蝥胶囊联合TAC方案治疗三阴性乳腺癌的疗效。方法 选取2020年4月—2023年3月在东台市中医院就诊的100例三阴性乳腺癌患者，根据随机数字表法将100例患者分为对照组（50例）和治疗组（50例）。对照组给予TAC方案治疗，第1天静脉注射多西他赛注射液75 mg/m²、静脉滴注注射用环磷酰胺600 mg/m²、静脉注射注射用盐酸表柔比星80 mg/m²。治疗组在对照组基础上口服复方斑蝥胶囊，3粒/次，2次/d。以21 d为1个化疗周期，两组在持续治疗6个周期后分析疗效。比较两组的临床疗效、生活质量、淋巴细胞相关指标、肿瘤标志物、血清指标和不良反应的情况。结果 治疗后，治疗组的总有效率（94.00%）高于对照组（80.00%），组间比较差异显著（P＜0.05）。治疗后，两组的乳腺癌生活质量量表（QLSBC）评分低于治疗前（P＜0.05），且治疗组QLSBC评分低于对照组（P＜0.05）。治疗后，治疗组的CD8⁺比治疗前小，LMR、CD4⁺、CD4⁺/CD8⁺比治疗前大（P＜0.05）；治疗组的CD8⁺比对照组小，LMR、CD4⁺、CD4⁺/CD8⁺比对照组大（P＜0.05）。治疗后，两组的血清糖蛋白抗原（CA153）、癌胚抗原（CEA）水平均比治疗前低（P＜0.05）；治疗组血清CA153、CEA水平比对照组低（P＜0.05）。治疗后，两组的血清脂联素（ADP）水平高于治疗前，血清白细胞介素-8（IL-8）水平低于治疗前（P＜0.05）；治疗组的血清ADP水平高于对照组，血清IL-8水平低于对照组（P＜0.05）。治疗期间，治疗组的不良反应发生率比对照组低，组间比较差异显著（P＜0.05）。结论 复方斑蝥胶囊联合TAC方案有助于提高三阴性乳腺癌的疗效，有助于改善患者的免疫功能和生活质量，降低肿瘤标志物的水平和药物不良反应的发生。

Objective To investigate the efficacy of Compound Banmao Capsules combined with TAC regimen in treatment of triple negative breast cancer. Methods Patients (100 cases) with triple negative breast cancer in Dongtai Hospital of TCM from April 2020 to March 2023 were divided into control and treatment groups according to the random number table method, and each group had 50 cases. Patients in the control group was treated with TAC regimen. On the first day, patients in the control group received intravenous injection of 75 mg/m² of Docetaxel Injection, intravenous drip of 600 mg/m² of Cyclophosphamide for injection, and intravenous injection of 80 mg/m² of Epirubicin Hydrochloride Injection. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 3 grains/time, twice daily. One chemotherapy cycle had 21 days, and the efficacy of the two groups was analyzed after continuous treatment for 6 cycles.The clinical efficacies, Quality of life, lymphocyte related indicators, tumor markers and serum indicators, and adverse reactions in two groups were compared. Results After treatment, the total effective rate of the treatment group (94.00%) was higher than that of the control group (80.00%), and the difference between groups was significant (P＜0.05). After treatment, the QLSBC score of breast cancer in two groups was lower than that before treatment (P＜0.05), and the QLSBC score in the treatment group was lower than that in the control group (P＜0.05). After treatment, CD8⁺ in the treatment group was smaller than before treatment, but LMR, CD4⁺, CD4⁺/CD8⁺ were larger than those before treatment (P＜0.05). CD8⁺ in the treatment group was smaller than that in the control group, while LMR, CD4⁺, CD4⁺/CD8⁺ were larger than those in the control group (P＜ 0.05). After treatment, the serum levels of CA153 and CEA in two groups were lower than those before treatment (P＜0.05). The serum levels of CA153 and CEA in the treatment group were lower than those in the control group (P＜0.05). After treatment, the serum levels of ADP in two groups were higher than those before treatment, but the serum levels of IL-8 were lower than before treatment (P＜0.05). The serum level of ADP in the treatment group was higher than that in the control group, but the serum level of IL-8 was lower than that in the control group (P＜0.05). During the treatment period, the incidence of adverse reactions in the treatment group was lower than that in the control group, and there was a significant difference between the groups (P＜0.05). Conclusion Compound Banmao Capsules combined with TAC regimen is helpful to improve the efficacy of triple negative breast cancer, improve the immune function and quality of life of patients, reduce the level of tumor markers, and reduce the occurrence of adverse drug reactions.

R979.1

盐城市科技项目（YCBE202235）